At the 20% threshold often considered clinically transformative nearly twice as many tirzepatide patients (55%) achieved it compared to semaglutide (28%)
Potential side effects may include: Certain medical conditions may increase the risk of side effects or make the Resilience Boost treatments unsuitable, including: These topics will also be covered in your individual consultation with our medical providers before prescribing
GLP-1s should be used cautiously in patients with a history of pancreatitis, but its not a contraindication
Recommended Dosage and Timing There is no one-size-fits-all answer for dosing, but general guidelines exist
W., Kim S
A., Dvorkin, E., Homel, P., Culliney, B., Malamud, S., Shaiova, L., Fleishman, S., Lapin, J., Klein, E., Lesage, P., Portenoy, R., & EstebanCruciani, N